Shah Wealth Advisors LLC Makes New $681,000 Investment in Novartis AG $NVS

Shah Wealth Advisors LLC purchased a new stake in Novartis AG (NYSE:NVS) during the second quarter, according to its most recent filing with the SEC. The firm purchased 4,346 shares of the company’s stock, valued at approximately $681,000.

Several other hedge funds also recently bought and sold shares of the company. Auto Owners Insurance Co grew its stake in Novartis by 13,687.0% in the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company’s stock valued at $638,103,000 after acquiring an additional 4,594,726 shares during the period. WCM Investment Management LLC acquired a new position in Novartis in the 1st quarter worth $220,004,000. Morgan Stanley increased its holdings in Novartis by 14.9% during the 4th quarter. Morgan Stanley now owns 8,876,906 shares of the company’s stock worth $1,223,860,000 after purchasing an additional 1,148,033 shares in the last quarter. GQG Partners LLC raised its stake in shares of Novartis by 39.6% in the 4th quarter. GQG Partners LLC now owns 3,158,122 shares of the company’s stock valued at $435,414,000 after purchasing an additional 895,255 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Novartis in the fourth quarter valued at about $108,638,000. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis reported that remibrutinib met the primary endpoint in two Phase 3 trials for relapsing multiple sclerosis. The result supports the potential expansion of the drug beyond its existing development opportunities. Novartis Remibrutinib Phase 3 Trial Results
• Neutral Sentiment: Novartis’ recent Basel-related move and a reported multibillion-dollar investment to improve how an existing medicine is delivered point to a shift in strategic priorities. The initiative could support product differentiation and lifecycle management, although its financial impact is not yet clear. Novartis Basel Strategic Move
• Neutral Sentiment: Options traders purchased a large volume of Novartis put contracts, signaling increased near-term hedging or bearish speculation. This reflects market sentiment rather than a change in the company’s fundamentals. Novartis Put Option Activity
• Negative Sentiment: Novartis and partner Ionis Pharmaceuticals said pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial. The setback weakens the outlook for a closely watched treatment targeting lipoprotein(a), a major potential growth opportunity in cardiovascular medicine. Pelacarsen Late-Stage Trial Failure
• Negative Sentiment: Novartis paused eight experimental rap-cel CAR-T trials after three patient deaths linked to severe immune reactions. The safety issue threatens development of the company’s autoimmune and neurological cell-therapy programs and raises regulatory and disclosure concerns. Novartis CAR-T Trial Halt
• Negative Sentiment: Erste Group Bank lowered its earnings estimates for Novartis, adding pressure to expectations for future results. Combined with the pelacarsen failure and CAR-T safety pause, the revisions reinforce concerns about pipeline execution. Erste Group Cuts Novartis Earnings Estimates

Analysts Set New Price Targets

NVS has been the topic of a number of recent research reports. Citigroup reissued a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research note on Friday, July 24th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Novartis presently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

NYSE:NVS opened at $159.95 on Friday. The stock has a market capitalization of $305.21 billion, a PE ratio of 24.13, a P/E/G ratio of 3.18 and a beta of 0.45. Novartis AG has a 1-year low of $121.57 and a 1-year high of $170.46. The firm has a fifty day simple moving average of $155.74 and a 200 day simple moving average of $153.78. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. On average, research analysts expect that Novartis AG will post 8.84 EPS for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.